ABSTRACT
Background: SARs-Cov-2 infections can produce prolonged illness and significant disability. Patients recovering from COVID-19 can have persistent symptoms leading to long-term morbidity. Methods: Six patients with long-lasting (> 30 days) COVID-19 symptoms were treated with hyperbaric oxygen (HBO2) therapy. All patients were assessed for symptoms using the ImPACT questionnaire, a muscle and joint pain scale, and a modified Borg dyspnea scale. Patients were assessed before, during and after HBO2 treatments. Results: All patients saw improvements in the measured symptoms to levels that were the same as pre-infection levels (five of six patients) or had significant improvement in symptoms (one patient). Conclusion: The results suggest that HBO2 helped to improve symptom scores, reduce the length of time of symptoms, and improved the quality of life. More detailed and randomized studies are needed to confirm the results in this report.
Subject(s)
COVID-19 , Hyperbaric Oxygenation , COVID-19/therapy , Humans , Quality of LifeABSTRACT
EVIDENCE-BASED ANSWER: Topical permethrin is the most effective treatment for classic scabies (strength of recommendation [SOR]: A, meta-analyses with consistent results). Topical lindane and crotamiton are inferior to permethrin but appear equivalent to each other and benzyl benzoate, sulfur, and natural synergized pyrethrins (SOR: B, limited randomized trials). Although not as effective as topical permethrin, oral ivermectin is an effective treatment compared with placebo (SOR: B, a single small randomized trial). Oral ivermectin may reduce the prevalence of scabies at one year in populations with endemic disease more than topical permethrin (SOR: B, a single randomized trial).
Subject(s)
Antiparasitic Agents/therapeutic use , Benzoates/therapeutic use , Hexachlorocyclohexane/therapeutic use , Insecticides/therapeutic use , Scabies/drug therapy , Administration, Oral , Administration, Topical , Animals , Humans , Sarcoptes scabiei/drug effects , Sulfur/therapeutic use , Toluidines/therapeutic useABSTRACT
Recombinant human thyrotropin (rhTSH)-stimulated serum thyroglobulin (Tg) level alone is sufficient to monitor for recurrent disease in low-risk patients with a history of differentiated thyroid cancer (DTC). Low-risk patients are defined as patients who have undergone total thyroidectomy and radioactive iodine (I(131)) remnant ablation therapy and show no clinical evidence of recurrent disease.
